Relay Therapeutics ( NASDAQ:RLAY – Get Rating ) had its price target reduced by JPMorgan Chase & Co. from $45.00 to $42.00 in a research note issued to investors on Wednesday, Benzinga reports. They currently have an overweight rating on the stock. Several other research analysts have also recently weighed in on RLAY. Guggenheim decreased their target price on Relay Therapeutics from $45.00 to $28.00 in a research note on Thursday, March 9th. HC Wainwright upped their price target on Relay Therapeutics from $43.

https://www.dailypolitical.com/2023/04/08/relay-therapeutics-nasdaqrlay-price-target-cut-to-42-00-by-analysts-at-jpmorgan-chase-co.html

#dailypolitical